Thomas K. Eigentler

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part IV: Palliative Management of Painful Bone Metastases, Pain Relief - and Beyond.

Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Published: August 16, 2026

Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 11, 2026

Tildrakizumab resolves multirefractory immune checkpoint inhibitor-induced colitis in metastatic melanoma.

Journal: Clinics and research in hepatology and gastroenterology

Published: April 12, 2026

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part III: Transcranial Application, Immune Profile, Blood-Brain Barrier, Neuroprotection, Neuromodulation and Neurostimulation.

Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Published: April 04, 2026

Years of life lost in cutaneous squamous cell carcinoma: analysis of a prospective cohort of 1400 patients.

Journal: Journal of cancer research and clinical oncology

Published: March 21, 2026

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part II: Biomechanics, Computational Simulation, Technical Generator and Applicator Design, and Physiological Effect.

Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Published: January 13, 2026

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part II: Biomechanics, Computational Simulation, Technical Generator and Applicator Design, and Physiological Effect.

Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Published: January 13, 2026

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part I: Animal Experiments, Clinical Application and Immunological Abscopal Effect.

Journal: Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology

Published: November 03, 2025

Correction: Hassel et al. Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. Cancers 2023, 15, 3448.

Journal: Cancers

Published: September 18, 2025

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

Journal: Nature communications

Published: July 24, 2025

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part IV: Palliative Management of Painful Bone Metastases, Pain Relief - and Beyond.

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part IV: Palliative Management of Painful Bone Metastases, Pain Relief - and Beyond.

Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

Tildrakizumab resolves multirefractory immune checkpoint inhibitor-induced colitis in metastatic melanoma.

Tildrakizumab resolves multirefractory immune checkpoint inhibitor-induced colitis in metastatic melanoma.

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part III: Transcranial Application, Immune Profile, Blood-Brain Barrier, Neuroprotection, Neuromodulation and Neurostimulation.

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part III: Transcranial Application, Immune Profile, Blood-Brain Barrier, Neuroprotection, Neuromodulation and Neurostimulation.

Years of life lost in cutaneous squamous cell carcinoma: analysis of a prospective cohort of 1400 patients.

Years of life lost in cutaneous squamous cell carcinoma: analysis of a prospective cohort of 1400 patients.

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part II: Biomechanics, Computational Simulation, Technical Generator and Applicator Design, and Physiological Effect.

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part II: Biomechanics, Computational Simulation, Technical Generator and Applicator Design, and Physiological Effect.

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part II: Biomechanics, Computational Simulation, Technical Generator and Applicator Design, and Physiological Effect.

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part II: Biomechanics, Computational Simulation, Technical Generator and Applicator Design, and Physiological Effect.

European Standard Clinical Practice Recommendations for Cutaneous Melanoma in Children and Adolescents.

European Standard Clinical Practice Recommendations for Cutaneous Melanoma in Children and Adolescents.

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.

Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part I: Animal Experiments, Clinical Application and Immunological Abscopal Effect.

Tumor Destructive Mechanical Impulse (TMI) Treatment of Solid Tumors. Part I: Animal Experiments, Clinical Application and Immunological Abscopal Effect.

Correction: Hassel et al. Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. Cancers 2023, 15, 3448.

Correction: Hassel et al. Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition. Cancers 2023, 15, 3448.

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.